Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Centogene stock logo
CNTG
Centogene
$0.17
$0.25
$1.53
$8.80M-0.67150,868 shs8.36 million shs
DermTech, Inc. stock logo
DMTK
DermTech
$0.19
$0.09
$3.90
$3.29M2.481.07 million shs3.66 million shs
RadNet, Inc. stock logo
RDNT
RadNet
$55.48
-3.5%
$57.05
$45.00
$93.65
$4.16B1.41683,687 shs421,167 shs
Renalytix Plc stock logo
RNLX
Renalytix
$0.21
$0.23
$0.18
$2.40
$17.18M2.721.45 million shs934,496 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Centogene stock logo
CNTG
Centogene
0.00%0.00%0.00%0.00%-68.61%
DermTech, Inc. stock logo
DMTK
DermTech
0.00%0.00%0.00%0.00%+6.45%
RadNet, Inc. stock logo
RDNT
RadNet
0.00%-1.21%-1.94%+3.88%-1.32%
Renalytix Plc stock logo
RNLX
Renalytix
0.00%0.00%0.00%0.00%-31.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Centogene stock logo
CNTG
Centogene
N/AN/AN/AN/AN/AN/AN/AN/A
DermTech, Inc. stock logo
DMTK
DermTech
N/AN/AN/AN/AN/AN/AN/AN/A
RadNet, Inc. stock logo
RDNT
RadNet
4.269 of 5 stars
3.82.00.04.62.92.50.0
Renalytix Plc stock logo
RNLX
Renalytix
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Centogene stock logo
CNTG
Centogene
0.00
N/AN/AN/A
DermTech, Inc. stock logo
DMTK
DermTech
0.00
N/AN/AN/A
RadNet, Inc. stock logo
RDNT
RadNet
3.50
Strong Buy$69.6025.45% Upside
Renalytix Plc stock logo
RNLX
Renalytix
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest DMTK, RNLX, RDNT, and CNTG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
RadNet, Inc. stock logo
RDNT
RadNet
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$74.00
6/13/2025
RadNet, Inc. stock logo
RDNT
RadNet
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$69.00
6/12/2025
RadNet, Inc. stock logo
RDNT
RadNet
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy ➝ Strong-Buy
(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Centogene stock logo
CNTG
Centogene
$48.54M0.00N/AN/A($1.01) per share0.00
DermTech, Inc. stock logo
DMTK
DermTech
$15.66M0.00N/AN/A$1.67 per share0.00
RadNet, Inc. stock logo
RDNT
RadNet
$1.83B2.28$3.48 per share15.93$15.31 per share3.62
Renalytix Plc stock logo
RNLX
Renalytix
$2.29M7.50N/AN/A($0.10) per share-2.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Centogene stock logo
CNTG
Centogene
-$38.58MN/A0.00N/AN/AN/AN/AN/AN/A
DermTech, Inc. stock logo
DMTK
DermTech
-$100.89M-$2.70N/AN/AN/A-572.19%-138.79%-68.96%N/A
RadNet, Inc. stock logo
RDNT
RadNet
$2.79M-$0.43N/A104.68N/A-1.73%1.41%0.48%8/6/2025 (Estimated)
Renalytix Plc stock logo
RNLX
Renalytix
-$33.46M-$0.39N/AN/A-1,461.60%N/A-281.40%N/A

Latest DMTK, RNLX, RDNT, and CNTG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
RadNet, Inc. stock logo
RDNT
RadNet
$0.17N/AN/AN/A$488.06 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Centogene stock logo
CNTG
Centogene
N/AN/AN/AN/AN/A
DermTech, Inc. stock logo
DMTK
DermTech
N/AN/AN/AN/AN/A
RadNet, Inc. stock logo
RDNT
RadNet
N/AN/AN/AN/AN/A
Renalytix Plc stock logo
RNLX
Renalytix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Centogene stock logo
CNTG
Centogene
N/A
1.02
0.96
DermTech, Inc. stock logo
DMTK
DermTech
N/A
3.53
3.46
RadNet, Inc. stock logo
RDNT
RadNet
0.87
2.01
2.01
Renalytix Plc stock logo
RNLX
Renalytix
N/A
0.53
0.53

Institutional Ownership

CompanyInstitutional Ownership
Centogene stock logo
CNTG
Centogene
9.94%
DermTech, Inc. stock logo
DMTK
DermTech
20.45%
RadNet, Inc. stock logo
RDNT
RadNet
77.90%
Renalytix Plc stock logo
RNLX
Renalytix
9.92%

Insider Ownership

CompanyInsider Ownership
Centogene stock logo
CNTG
Centogene
1.93%
DermTech, Inc. stock logo
DMTK
DermTech
5.10%
RadNet, Inc. stock logo
RDNT
RadNet
5.60%
Renalytix Plc stock logo
RNLX
Renalytix
18.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Centogene stock logo
CNTG
Centogene
81027.08 millionN/ANot Optionable
DermTech, Inc. stock logo
DMTK
DermTech
26034.96 million33.18 millionOptionable
RadNet, Inc. stock logo
RDNT
RadNet
11,02175.03 million70.83 millionOptionable
Renalytix Plc stock logo
RNLX
Renalytix
10082.96 million63.06 millionOptionable

Recent News About These Companies

Renalytix Adjusts Share Capital Amid Fundraising Shortfall
Renalytix AI earnings: here's what Wall Street expects

New MarketBeat Followers Over Time

Media Sentiment Over Time

Centogene stock logo

Centogene NASDAQ:CNTG

Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.

DermTech stock logo

DermTech NASDAQ:DMTK

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

RadNet stock logo

RadNet NASDAQ:RDNT

$55.48 -2.02 (-3.51%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$55.50 +0.02 (+0.03%)
As of 07/11/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Renalytix stock logo

Renalytix NASDAQ:RNLX

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.